Clariant Chemicals Q1 profits up by 20.3% Sales grew by 11.9%

Emirates PharmaAdvertisement

Clariant Chemicals (India) Limited reported profit before tax of Rs. 18.4 crore for the quarter ended June 2019, as compared to profit before tax of Rs. 15.3 crore for the quarter ended June 2018 – a growth of 20.3%.

The Company reported sales growth of 11.9%, at Rs. 295.8 crore, for the quarter ended June 2019, as against Rs. 264.3 crore for the corresponding quarter in the previous year.

“Clariant has delivered a robust quarter with a relentless focus on costs, backed by a product portfolio powered by value added offerings. Clariant continues to execute its strategy to deliver shareholder value.

Our ongoing emphasis on delivering strong financial results in the short term, while building a sustainable business for the future through excellence in Safety, Compliance and Customer Centricity continues,” explained Adnan Ahmad, Vice-Chairman & Managing Director

Clariant is a focused and innovative specialty chemical company, based in Muttenz near Basel/Switzerland. On 31 December 2018 the company employed a total workforce of 17 901. In the financial year 2018, Clariant recorded sales of CHF 4.404 billion for its continuing businesses. The company reports in three business areas: Care Chemicals, Catalysis and Natural Resources. Clariant’s corporate strategy is based on five pillars: focus on innovation and R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability.

Clariant’s listed entity in India – Clariant Chemicals (India) Ltd, headquartered in Mumbai includes the businesses Pigments, Masterbatches and Additives, which deliver solutions for the emerging industry sectors in India. The 780-plus employee strength generated sales of INR 9.84 billion for the 12 months ended March 31, 2019. Clariant has also invested in a state-of-the-art Regional Innovation Center in Mumbai, with an aim to co-create tailor-made solutions with customers for the industry www.clariant.com

Emirates PharmaAdvertisement